Permeability of porcine nasal mucosa correlated with human nasal absorption

European Journal of Pharmaceutical Sciences

Volumn 18, Issue 1, 2003, Pages 47-53

  Wadell, Cecilia ^a,b   Björk, Erik ^b   Camber, Ola ^c  

^a ASTRAZENECA R AND D   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c InDex Diagnostics AB   (Sweden)

Author keywords

Electrophysiology; Human; Nasal mucosa; Permeability; Pig; Ussing chamber

Indexed keywords

CORRELATION THEORY; DIFFUSION; ELECTROPHYSIOLOGY; ETHERS; HYDRAULIC CONDUCTIVITY; INSULIN; MOLECULES;

NASAL MUCOSA;

DRUG PRODUCTS;

AMINO DIETHER; ETHER DERIVATIVE; INSULIN; LIDOCAINE; MACROGOL 4000; MELAGATRAN; NICOTINE; PROPRANOLOL; SUMATRIPTAN; UNCLASSIFIED DRUG;

ACTIVE TRANSPORT; ANIMAL TISSUE; ARTICLE; CHEMICAL STRUCTURE; COMPARATIVE STUDY; CORRELATION ANALYSIS; DIFFUSION CHAMBER; DRUG ABSORPTION; DRUG MECHANISM; DRUG PENETRATION; EFFUSION; ELECTROPHYSIOLOGY; MEDICAL LITERATURE; MODEL; NONHUMAN; NOSE MUCOSA; PASSIVE TRANSPORT; PERMEABILITY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SWINE;

EID: 0037244130     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-0987(02)00240-3     Document Type: Article

References (55)

1. Amidon G.L., Lennernäs H., Shah V.P., Crison J.R. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 12:(3):1995;413-420.
2. Artursson P. Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. J. Pharm. Sci. 79:(6):1990;476-482.
3. Artursson P., Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun. 175:1991;880-885.
4. Artursson P., Palm K., Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv. Drug Del. Rev. 46:2001;27-43.
5. Artursson P., Ungell A.-L., Löfroth J.-E. Selective paracellular permeability in two models of intestinal absorption: cultured monolayers of human intestinal epithelial cells and rat intestinal segments. Pharm. Res. 10:(8):1993;1123-1128.
6. Bechgaard E., Gizurarson S., Jørgensen L., Larsen R. The viability of isolated rabbit nasal mucosa in the Ussing chamber, and the permeability of insulin across the membrane. Int. J. Pharm. 87:1992;125-132.
7. Bechgaard E., Jørgensen L., Larsen R., Gizurarson S., Carstensen J., Hvass A. Insulin and didecanoyl-L-alfa-phosphatidylcholine: in vitro study of transport through rabbit nasal mucosal tissue. Int. J. Pharm. 89:1993;147-153.
8. Behl C.R., Pimplaskar H.K., Sileno A.P., deMeireles J., Romeo V.D. Effects of physicochemical properties and other factors on systemic nasal drug delivery. Adv. Drug Del. Rev. 29:1998;89-116.
9. Carstens S., Danielsen G., Guldhammer B., Frederiksen O. Transport of insulin across rabbit nasal mucosa in vitro induced by didecanoyl-L-alpha-phosphatidylcholine. Diabetes. 42:(7):1993;1032-1040.
10. Chiou W.l., Chung S.M., Wu T.C., Mu C. A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans. Int. J. Clin. Pharmacol. Ther. 39:(3):2001;93-101.
11. Donovan M.D., Flynn G.L., Amidon G.L. Absorption of polyethylene glycols 600 through 2000: the molecular weight dependence of gastrointestinal and nasal absorption. Pharm. Res. 7:(8):1990;863-868.
12. Donovan M.D., Huang Y. Large molecule and particulate uptake in the nasal cavity: the effect of size on nasal absorption. Adv. Drug Del. Rev. 29:1998;147-155.
13. Dooley M., Spencer C.M., Ormrod D. Estradiol-intranasal A review of its use in the management of menopause. Drugs. 61:(15):2001;2243-2262.
14. Duquesnoy C., Mamet J.P., Sumner D., Fuseau E. Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration. Eur. J. Pharm. Sci. 6:1998;99-104.
15. Gizurarson S. Animal models for intranasal drug delivery studies. Acta. Pharm. Nord. 2:(2):1990;105-122.
16. Gizurarson S., Tamura S.-i., Kurata T., Hasiguchi K., Ogawa H. The effect of cholera toxin and cholera toxin B subunit on the nasal mucosal membrane. Vaccine. 9:1991;825-832.
17. Gustafsson D., Nyström J.-E., Carlsson S., Bredberg U., Eriksson U., Gyzander E., Elg M., Antonsson T., Hoffmann K.-J., Ungell A.-L., Sörensen H., Någård S., Abrahamsson A., Bylund R. The direct thrombin inhibitor Melagatran and its oral prodrug 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb. Res. 101:2001;171-181.
18. Henriksson G., Norlander T., Zheng X., Stierna P., Westrin K.M. Expression of p-glycoprotein 170 in nasal mucosa may be increased with topical steroids. Am. J. Rhinol. 11:1997;317-321.
19. Hosoya K., Kubo H., Natsume H., Sugibayashi K., Morimoto Y. Evaluation of enhancers to increase nasal absorption using Ussing chamber technique. Biol. Pharm. Bull. 17:(2):1994;316-322.
20. Hussain A., Foster T., Hirai S., Kashihara T., Batenhorst R., Jones M. Nasal absorption of propranolol in humans. J. Pharm. Sci. 69:(10):1980;1240.
21. Illum L. Nasal delivery. The use of animal models to predict performance in man. J. Drug Target. 3:1996;427-442.
22. Illum L., Watts P., Fisher A.N., Hinchcliffe M., Norbury H., Jabbal-GIll I., Nankervis R., Davis S.S. Intranasal delivery of morphine. J. Pharmacol. Exp. Ther. 301:(1):2002;391-400.
23. Johansson C.J., Olsson P., Bende M., Carlsson T., Gunnarsson P.O. Absolute bioavailability of nicotine applied to different nasal regions. Eur. J. Clin. Pharmacol. 41:1991;585-588.
24. Kimura R., Miwa M., Kato Y., Sato M., Yamada S. Relationship between nasal absorption and physicochemical properties of quaternary ammonium compounds. Arch. Int. Pharmacodyn. 310:1991;13-21.
25. Knoester P.D., Jonker D.M., Hoeven R.T.M.v.d., Vermeij T.A.C., Edelbroek P.M., Brekelmans G.J., Haan G.J.d. Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers. Br J Clin Pharmacol. 53:2002;501-507.
26. Kubo H., Hosoya K.-I., Natsume H., Sugibayashi K., Morimoto Y. In vitro permeation of several model drugs across rabbit nasal mucosa. Int. J. Pharm. 103:1994;27-36.
27. Lee C.-P., de Vrueh R.L.A., Smith P.L. Selection of development candidates based on in vitro permeability measurements. Adv. Drug Del. Rev. 23:1997;47-62.
28. Lennernäs H. Gastrointestinal absorption mechanisms: a comparison between animal and human models. Eur. J. Pharm. Sci. 2:1994;39-43.
29. Lennernäs H., Nylander S., Ungell A.-L. Jejunal permeability: a comparison between the Ussing chamber technique and the single-pass perfusion in humans. Pharm. Res. 14:(5):1997;667-671.
30. Lindhardt K., Bagger M., Andreasen K.H., Bechgaard E. Intranasal bioavailability of buprenorphine in rabbit correlated to sheep and man. Int. J. Pharm. 217:2001;121-126.
31. Lindhardt K., Gizurarson S., Stefansson S.B., Olafsson D.R., Bechgaard E. Electroencephalographic effects and serum concentrations after intranasal and intravenous administration of diazepam in healthy volunteers. Int. J. Pharm. 182:2001;1-5.
32. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Del. Rev. 23:1997;3-25.
33. Lonterman S., Asselt D.Z.B.v., Rikkert M.G.M.O., Russel F.G.M., Hoefnagels W.H.L., Merkus F.W.H.M. Intranasal hydroxycobalamin administration: an attractive alternative for intramuscular cobolamin injections in geriatric patients. Drug Dev. Res. 51:2000;197-199.
34. Marttin E., Verhoef J.C., Merkus F.W.H.M. Efficacy, safety and mechanism of cyclodextrins as absorption enhancers in nasal drug delivery of peptide and protein drugs. J. Drug Target. 6:(1):1998;17-36.
35. McMartin C., Hutchinson L.E.F., Hyde R., Peters G.E. Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity. J. Pharm. Sci. 76:(7):1987;535-540.
36. Merkus F.W.H.M., Verhoef J.C., Romeijn S.G., Schipper N.G.M. Interspecies differences in the nasal absorption of insulin. Pharm. Res. 8:(10):1991;1343.
37. Moses A.C., Gordon G.S., Carey M.C., Flier J.S. Insulin administered intranasally as an insulin-bile salt aerosol effectiveness and reproducibility in normal and diabetic subjects. Diabetes. 32:1983;1040-1047.
38. Palm K., Luthman K., Ungell A.-L., Strandlund G., Artursson P. Correlation of drug absorption with molecular surface properties. J. Pharm. Sci. 85:(1):1996;32-39.
39. Reardon P.M., Gochoco C.H., Audus K.L., Wilson G., Smith P.L. In vitro nasal transport across ovine mucosa: effects of ammonium glycyrrhizinate on electrical properties and permeability of growth hormone releasing peptide, mannitol, and lucifer yellow. Pharm. Res. 10:1993;553-561.
40. Sayani A.P., Chien Y.W. Systemic delivery of peptides and proteins across absorptive mucosae. Crit. Rev. Ther. Drug Carrier Syst. 13:(1&2):1996;85-184.
41. Scavone J.M., Greenblatt D.J., Fraser D.G. The bioavailability of intranasal lignocaine. Br. J. Clin. Pharmacol. 28:1989;722-724.
42. Schmidt M.C., Peter H., Lang S.R., Ditzinger G., Merkle H.P. In vitro cell models to study nasal mucosal permeability and metabolism. Adv. Drug Del. Rev. 29:1998;51-79.
43. Schmidt M.C., Simmen D., Hilbe M., Boderke P., Ditzinger G., Sandow J., Lang S.R., Rubas W., Merkle H.P. Validation of excised bovine nasal mucosa as in vitro model to study drug transport and metabolic pathways in nasal epithelium. J. Pharm. Sci. 89:(3):2000;396-407.
44. Schneider N.G., Lunell E., Olmstead R.E., Fagerström K.-O. Clinical pharmacokinetics of nasal nicotine delivery. A review and comparison to other nicotine systems. Clin. Pharmacokinet. 31:(1):1996;56-80.
45. Slot W.B., Merkus F.W.H.M., Deventer S.J.H.v., Tytgat G.N.J. Normalization of plasma vitamin B12 concentration by intranasal hydroxycobolamin in vitamin B12-deficient patients. Gastroenterology. 113:1997;430-433.
46. Stewart B.H., Chan O.H., Jezyk N., Fleisher D. Discrimination between drug candidates using models for evaluation of intestinal absorption. Adv. Drug Del. Rev. 23:1997;27-45.
47. Suzuki K., Kawahara K., Terada N., Nomura T., Konno A., Fukuda Y. Effect of ion transport inhibitors and methacholine on short-circuit current of isolated guinea pig nasal epithelium. Jpn. J. Physiol. 49:1999;99-106.
48. Ungell A.-L. In vitro absorption studies and their relevance to absorption from the GI tract. Drug Dev. Ind. Pharm. 23:(9):1997;879-892.
49. Wadell C., Björk E., Camber O. Nasal drug delivery-evaluation of an in vitro method using porcine nasal mucosa. Eur. J. Pharm. Sci. 7:1999;197-206.
50. Walgren R.A., Walle T. The influence of plasma binding on absorption/exsorption in the Caco-2 model of human intestinal absorption. J. Pharm. Pharmacol. 51:1999;1037-1040.
51. Werner U., Kissel T. In-vitro cell culture models of the nasal epithelium: a comparative histochemical investigation of their suitability for drug transport studies. Pharm. Res. 13:(7):1996;978-988.
52. Wheatley M.A., Dent J., Wheeldon E.B., Smith P.L. Nasal drug delivery: an in vitro characterization of transepithelial electrical properties and fluxes in the presence or absence of enhancers. J. Control. Release. 8:1988;167-177.
53. Winiwarter S., Bonham N.M., Ax F., Hallberg A., Lennernäs H., Karlén A. Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach. J. Med. Chem. 41:1998;4939-4949.
54. Wioland M.-A., Fleury-Feith J., Corlieu P., Commo F., Monceaux G., Lacau-St-Guily J., Bernaudin J.-F. CFTR, MDR1 and MRP1 immunolocalization in normal human nasal respiratory mucosa. J. Histochem. Cytochem. 48:(9):2000;1215-1222.
55. Yee S. In vitro permeability across caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man-fact or myth. Pharm. Res. 14:(6):1997;763-766.